Inhibitory effect and mechanism of cinobufotalin on lung cancer NCI-A549 xenograft in nude mice

doi:10.12092/j.issn.1009-2501.2018.10.004

Abstract

Abstract:

AIM: To investigate the anti-tumor effect and mechanism of cinobufotalin on lung cancer cells NCI-A549. METHODS: Forty BALB/c nude mice were randomly divided into the normal group, the mock group, the cinobufotalin group and the DDP (cisplatin) group. Body weight change, tumor inhibition rate, blood function, liver and kidney function of the mice in each group were detected. Western blot was used to investigate the expression of apoptosis-associated proteins.RESULTS:Cinobufotalin significantly inhibited the growth of A549 xenograft, but had no significant effect on the blood, liver and kidney function of the mice. The tumor-inhibition rate of the cinobufotalin group and the DDP group was 58.0% and 82.3%, respectively. Western blot results showed that cinobufotalin significantly up-regulated the expression of Bax/Bcl-2, promoted the expression of cleaved-caspase-3, cleaved-PARP, and inhibited the expression of p-AKT(ser473). CONCLUSION: Cinobufotalin can significantly inhibit the growth of lung cancer A549 xenograft. Its molecular mechanism might be related to the inhibition of PI3K/AKT pathway activation. Based on this mechanism, cinobufotalin can accelerate cell apoptosis.

Key words: cinobufotalin, lung cancer, xenograft, apoptosis, PI3K/AKT pathway

CLC Number:

R965.2

XIONG Fei, SHI Yanyan, SHEN Jiucheng, CHENG Honglan, HANG Yongfu. Inhibitory effect and mechanism of cinobufotalin on lung cancer NCI-A549 xenograft in nude mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1103-1108.

References

［1］Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(3): 177-193.
［2］Schwartz AG, Cote ML. Epidemiology of lung cancer［J］. Cancer Personal Med, 2016, 893(52): 21-41.
［3］Zhu J, Li R, Tiselius E, et al. Immunotherapy (excludingcheckpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent［J］.Cochrane Database Syst Rev, 2017, 12: CD011300.
［4］Tabchi S, Kassouf E, Rassy EE, et al. Management of stage III non-small cell lung cancer［J］. Semin Oncol, 2017, 44 (3): 163-177.
［5］Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer［J］. Expert Rev Anticancer Ther, 2018, 18 (1): 63-70.
［6］Cheng L, Shi L, Wu J, et al. A hederagenin saponin isolated from Clematis ganpiniana induces apoptosis in breast cancer cells via the mitochondrial pathway［J］. Oncol Lett, 2018, 15(2): 1737-1743.
［7］董海鹰, 王知非. 青蒿琥酯对人乳腺癌MCF-7血管生成和肿瘤浸润作用研究［J］. 中国临床药理学与治疗学, 2015, 20(5): 537-540.
［8］魏玉林, 王淑美, 刘启欧, 等. 益气除痰方调控内质网应激蛋白ATF4、CHOP治疗肺癌机理研究［J］. 中国临床药理学与治疗学, 2016, 21(6): 601-605.
［9］李英夫, 宣兆博, 廉晓宇. 榄香烯诱导SHG－44细胞凋亡和对细胞周期各时相的影响［J］. 中医药信息, 2016, 33(6): 11-12.
［10］薛刚, 邹玺, 周锦勇, 等. 竹节香附素A对人胃癌细胞株BGC-823细胞周期及STAT3信号通路的影响［J］. 南京中医药大学学报, 2017, 33(1): 78-81.
［11］冯全服, 毕蕾, 颜晓静, 等. 川芎嗪调控肝癌HepG2细胞凋亡及对相关蛋白表达的影响［J］. 南京中医药大学学报, 2017, 31(3): 246-249.
［12］Chen T, Yuan SJ, Wang J, et al. Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model［J］. World J Gastroenterol, 2015, 21(35): 10126-10136.
［13］Afroze SH, Sloan J, Osuji GC, et al. Cinobufotalin impedes Sw.71 cytotrophoblast cell line function via cell cycle arrest and apoptotic signaling［J］. Mol Cell Biochem, 2016, 422(1-2): 189-196.
［14］ Liu Q, Yang H, Xu S, et al. Downregulation of p300 alleviates LPS-induced inflammatory injuries through regulation of RhoA/ROCK/NF-κB pathways in A549 cells［J］. Biomed Pharmacother, 2018, 97: 369-374.
［15］张萍. 紫草素对人肝癌HepG2 细胞生长的影响及机制研究［J］. 中医药信息, 2017, 34(4): 10-14.
［16］壮雨雯, 周锦勇, 吴坚, 等. 澳洲茄胺诱导肠癌HCT-116细胞凋亡的实验研究［J］. 南京中医药大学学报, 2017, 33(1): 69-73.
［17］Park C, Lee WS, Han MH, et al. Lonicera japonica Thunb. Induces caspase-dependent apoptosis through death receptors and suppression of AKT in U937 human leukemic cells［J］. Phytother Res, 2017, doi: 10.1002/ptr.5996.
［18］Shim MK, Yoon HY, Lee S, et al. Caspase-3/-7-Specific metabolic precursor for bioorthogonal tracking of tumor apoptosis［J］. Sci Rep, 2017, 7(1): 16635.
［19］Hou T, Zhou L, Wang L, et al. CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway［J］. Oncotarget, 2017, 8(54): 93001-93013.
［20］Zhao J, Zhu J, Lv X, et al. Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF-κB/COX-2 signaling pathways［J］. Onco Targets Ther, 2017, 10: 5471-5482.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[3]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[4]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[5]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[6]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[7]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[8]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[9]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[10]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[11]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[12]	SU Yang, ZHOU Feng, DING Jinlei. Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
[13]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[14]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[15]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.